Novartis
East Hanover, New Jersey, 07936, United States
Location status: Recruiting
NCT Number: NCT07635316
This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical Claims (Dx) databases supplemented with mortality data.
Interested in participating?
Request Info18 year–110 year
All sexes
Observational
East Hanover, New Jersey, 07936, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Up to approximately 8 years
Time frame: Up to approximately 8 years
Time frame: Up to approximately 8 years
Time frame: Up to approximately 8 years
Time frame: Up to approximately 8 years
Time frame: Up to approximately 8 years
Time frame: Baseline
Time frame: Up to approximately 8 years
Time frame: Up to approximately 8 years
Time frame: Up to approximately 8 years
Time frame: Up to approximately 8 years
OS calculated as the number of weeks from the start of treatment until death.
Time frame: Baseline
Demographics include:
Time frame: Baseline
Time frame: Up to approximately 8 years
Time frame: Baseline
Clinical characteristics include:
Time frame: Baseline
The NCI comorbidity index is a tool used to measure the risk of non-cancer deaths for cancer patients based on the presence and severity of other health conditions. It includes 14 conditions identified using administrative data diagnosis and procedure codes. The index excludes solid tumors, leukemias, and lymphomas as comorbid conditions. Each condition is assigned a score (from 1 to 6) based on how serious it is and patient scores are summed to give a final overall score. A high score indicates a higher burden of comorbid conditions and possible higher risk of death.
Contact information is provided by the study sponsor or research team.
Novartis Pharmaceuticals
Industry
Treatment Patterns and Outcomes in GEP NET: A Retrospective Observational Cohort Study (PRIME Initiative)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07165132
Adenocarcinoma, Adenoma
Iowa City, Iowa, United States
View Trial DetailsNCT05636618
Bronchial Neuroendocrine Tumor, Central Nervous System Neoplasms
Jacksonville, Florida, United States
View Trial DetailsNCT05477576
Adenocarcinoma, Adenoma
Phoenix, Arizona, United States
View Trial DetailsNCT04090034
Gastro-enteropancreatic neuroendocrine tumor, Gastroenteropancreatic Neuroendocrine Tumor
Dallas, Texas, United States
View Trial Details